Premier Alternatives

iQure Pharma

Princeton, NJ · Founded 2019 · Privately Held (backing)

Developer of biopharmaceutical therapies designed to address central nervous system disorders by restoring glutamate homeostasis. iQure Pharma is based in Princeton, NJ and was founded in 2019. Its last reported valuation was $21 million in Nov 2025. It has raised $13.1 million across 4 recorded rounds; the latest was a $650,000 seed round in May 2026.

Last reported valuation
$21.0M
Oct 2026
Priced at
—
Total raised
$13.1M
Last round
Seed Round
May 2026

iQure Pharma key facts

as of Oct 2026
  • Developer of biopharmaceutical therapies designed to address central nervous system disorders by restoring glutamate homeostasis.
  • iQure Pharma is valued at approximately $21.0M as of Oct 2026 (last reported valuation).
  • It has raised $13.1M across 4 recorded rounds; the latest was Seed Round ($650K) in May 2026.
  • Notable investors include Keiretsu Forum, Endless Frontier Labs, SideCar Angels, Accelerator Venture Partners, Mass Medical Angels — 8 tracked in total.
  • iQure Pharma has filed 3 Form Ds with the SEC since 2023, most recently Jan 2025 ($1.4M sold to 2 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$21.0M

iQure Pharma's last reported valuation, Nov 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of iQure Pharma with a free account
  • ·Watch iQure Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

iQure Pharma funding rounds

4 rounds
May 2026Seed Round$650KSEC filing▮
Sep 2025Seed Round$1.5MSEC filing▮
Dec 2024Debt$1.4MSEC filing▮
Oct 2023Seed Round$1.5MSEC filing▮
Full funding history →

iQure Pharma valuation

iQure Pharma's last reported valuation was $21 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.

How much has iQure Pharma raised?

iQure Pharma has raised $13.1 million in total; 4 of its rounds are on record, from 2023 on. The largest on record was a $650,000 seed round in May 2026.

iQure Pharma has filed 3 Form Ds with the SEC since 2023, most recently in Jan 2025 ($1.4 million sold to 2 investors).

iQure Pharma investors

8 investors are on record for iQure Pharma, including Keiretsu Forum, Endless Frontier Labs, SideCar Angels and Accelerator Venture Partners. The seed round in May 2026 drew 1 investor.

About iQure Pharma

Developer of biopharmaceutical therapies designed to address central nervous system disorders by restoring glutamate homeostasis. The company focuses on enhancing astrocytic regulation of glutamate uptake to maintain synaptic balance and protect neurons from overstimulation, enabling the prevention of excitotoxicity-driven neuronal damage and disease progression across a broad range of neurological conditions.

Sector
Healthcare
HQ
Princeton, NJ, United States
Founded
2019
Employees
8
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.